Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312040 | 0.94 | TSHR (0.47) | KCNH2EPHX1TSHRKCNJ1SIRT2 | |
| SCHEMBL9762640 | 0.92 | TSHR (0.49) | KCNH2EPHX1TSHRKCNJ1SIRT2 | |
| SCHEMBL8727026 | 0.92 | TSHR (0.55) | KCNH2EPHX1TSHRKCNJ1IDO1 | |
| SCHEMBL11308396 | 0.92 | TSHR (0.55) | KCNH2EPHX1TSHRKCNJ1IDO1 | |
| SCHEMBL9165352 | 0.92 | TSHR (0.55) | KCNH2EPHX1TSHRKCNJ1IDO1 | |
| SCHEMBL7943874 | 0.91 | KCNH2 (0.59) | KCNH2TSHRKCNJ1SIRT2IDO1 | |
| SCHEMBL1312325 | 0.89 | TSHR (0.58) | KCNH2TSHRKCNJ1SIRT2IDO1 | |
| SCHEMBL10346573 | 0.88 | TSHR (0.60) | KCNH2EPHX1TSHRKCNJ1SIRT2 | |
| SCHEMBL378396 | 0.85 | TSHR (0.58) | KCNH2EPHX1TSHRKCNJ1IDO1 | |
| SCHEMBL19929796 | 0.85 | KCNH2 (0.66) | KCNH2EPHX1TSHRKCNJ1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2569285-A1 | BIFUNCTIONAL QUINOLINE DERIVATIVES | Gilead Sciences, Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20070249630-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | US | disclosed |
| US-4990505-A | Treating asthma, bronchitis; adrenergic stimulants | GLAXO GROUP LIMITED (GB) | 1991-02-05 | — | — | US | disclosed |
| US-4853381-A | Ethanolamine compounds | GLAXO GROUP LIMITED (GB) | 1989-08-01 | — | — | US | disclosed |
| US-4853382-A | TREATING ASTHMA AND BRONCHITIS | GLAXO GROUP LIMITED (GB) | 1989-08-01 | — | — | US | disclosed |
| EP-0178919-B1 | AMINOPHENOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1988-12-21 | — | — | EP | disclosed |
| US-4730008-A | STIMULANT FOR BETA-ADRENORECEPTORS | GLAXO GROUP LIMITED (GB) | 1988-03-08 | — | — | US | disclosed |
| EP-0223410-A2 | Ethanolamine Derivatives | GLAXO GROUP LIMITED (GB) | 1987-05-27 | — | — | EP | disclosed |
| EP-0178919-A2 | Aminophenol derivatives | GLAXO GROUP LIMITED (GB) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | KCNH2 586/4885EPHX1 64/4885TSHR 3793/4885 |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | BDKRB2, BDKRB1, P2RX7 | KCNH2 159/4885EPHX1 186/4885TSHR 2224/4885 |
| US-20070249630-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | KCNH2 586/4885EPHX1 64/4885TSHR 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.